| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
p-Methylphenyl potassium sulfate does not have a specific pharmacological target. It is a uremic toxin that accumulates in the blood of patients with chronic kidney disease (CKD). As a protein-bound uremic toxin, it is associated with cardiovascular disease and mortality in CKD patients.
|
|---|---|
| ln Vitro |
In vitro, p-Methylphenyl potassium sulfate is used as a research tool to study the effects of uremic toxins on cellular function. Its activity is assessed by measuring its effects on cell viability, inflammation, and oxidative stress in various cell types.
|
| ln Vivo |
In vivo, p-Methylphenyl potassium sulfate is a clinically relevant uremic toxin. Elevated levels of p-cresyl sulfate, the parent compound, are associated with cardiovascular disease and mortality in patients with chronic kidney disease.
|
| Enzyme Assay |
The in vitro assay for p-Methylphenyl potassium sulfate involves treating cells (e.g., endothelial cells, renal tubular cells) with the compound and measuring its effects on cell viability, inflammatory cytokine production, and oxidative stress markers.
|
| ADME/Pharmacokinetics |
p-Methylphenyl potassium sulfate has a molecular weight of 226.29 g/mol and is soluble in DMSO at ≥300 mg/mL. It is typically stored as a powder at -20°C. Its purity is >98%.
|
| Toxicity/Toxicokinetics |
Toxicological data for p-Methylphenyl potassium sulfate indicate that it is a uremic toxin that can contribute to the progression of chronic kidney disease and its complications. It is not intended for human use. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
p-Methylphenyl potassium sulfate is a research compound with no clinical approval. It is a valuable tool for studying the pathophysiology of chronic kidney disease and the role of uremic toxins in cardiovascular disease. It is used in research to develop new therapeutic strategies for reducing uremic toxin levels in CKD patients.
|
| Molecular Formula |
C7H7KO4S
|
|---|---|
| Molecular Weight |
226.2914
|
| Exact Mass |
225.97
|
| CAS # |
91978-69-7
|
| Related CAS # |
p-Cresol sulfate-d7 potassium; 2469278-96-2; p-Cresol sulfate-d4 potassium; p-Cresyl sulfate; 3233-58-7; p-Cresyl sulfate potassium; 91978-69-7
|
| PubChem CID |
91972090
|
| Appearance |
White to off-white solid powder
|
| Source |
Endogenously produced metabolite: Human Gut Microbiota Metabolites
|
| LogP |
1.914
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=S(OC1=CC=C(C)C=C1)(O[K])=O
|
| InChi Key |
HTSFIPMTBJHYFQ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C7H8O4S.K/c1-6-2-4-7(5-3-6)11-12(8,9)10;/h2-5H,1H3,(H,8,9,10);/q;+1/p-1
|
| Chemical Name |
potassium;(4-methylphenyl) sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~125 mg/mL (~552.4 mM; with ultrasonication and warming by heating to 60°C)
H2O: ≥ 100 mg/mL (~441.9 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (11.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. View More
Solubility in Formulation 4: 50 mg/mL (220.96 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), Clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4191 mL | 22.0955 mL | 44.1911 mL | |
| 5 mM | 0.8838 mL | 4.4191 mL | 8.8382 mL | |
| 10 mM | 0.4419 mL | 2.2096 mL | 4.4191 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
